$7.61
9.99% yesterday
Nasdaq, Nov 15, 10:16 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Target price 2024 - Analyst rating & recommendation

Altimmune, Inc. Classifications & Recommendation:

Buy
78%
Hold
22%

Altimmune, Inc. Price Target

Target Price $21.25
Price $7.61
Potential
Number of Estimates 8
8 Analysts have issued a price target Altimmune, Inc. 2025 . The average Altimmune, Inc. target price is $21.25. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend Altimmune, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Altimmune, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Altimmune, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.43 0.00
714.29% 99.12%
EBITDA Margin -19,309.30% -2,735,350.40%
115.51% 14,065.97%
Net Margin -27,455.63% -2,513,048.91%
114.93% 9,053.13%

8 Analysts have issued a sales forecast Altimmune, Inc. 2024 . The average Altimmune, Inc. sales estimate is

$3.8k
Unlock
. This is
92.40% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$20.0k 60.00%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $430k 714.29%
2024
$3.8k 99.12%
Unlock
2025
$25.0m 657,860.53%
Unlock
2026
$4.1k 99.98%
Unlock
2027
$55.2m 1,346,680.49%
Unlock
2028
$616m 1,016.45%
Unlock

3 Analysts have issued an Altimmune, Inc. EBITDA forecast 2024. The average Altimmune, Inc. EBITDA estimate is

$-103m
Unlock
. This is
5.29% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-99.0m 1.62%
Unlock
, the lowest is
$-106m 8.63%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-83.0m 4.73%
2024
$-103m 23.54%
Unlock
2025
$-119m 16.20%
Unlock
2026
$-140m 17.79%
Unlock
2027
$-133m 5.49%
Unlock
2028
$-9.2m 93.07%
Unlock

EBITDA Margin

2023 -19,309.30% 115.51%
2024
-2,735,350.40% 14,065.97%
Unlock
2025
-476.74% 99.98%
Unlock
2026
-3,407,865.41% 714,726.83%
Unlock
2027
-240.32% 99.99%
Unlock
2028
-1.49% 99.38%
Unlock

3 Altimmune, Inc. Analysts have issued a net profit forecast 2024. The average Altimmune, Inc. net profit estimate is

$-94.2m
Unlock
. This is
14.51% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-91.0m 17.42%
Unlock
, the lowest is
$-99.9m 9.34%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-118m 8.29%
2024
$-94.2m 20.18%
Unlock
2025
$-97.7m 3.69%
Unlock
2026
$-103m 5.80%
Unlock
2027
$-103m 0.26%
Unlock
2028
$-10.7m 89.65%
Unlock

Net Margin

2023 -27,455.63% 114.93%
2024
-2,513,048.91% 9,053.13%
Unlock
2025
-390.85% 99.98%
Unlock
2026
-2,509,420.87% 641,941.93%
Unlock
2027
-186.76% 99.99%
Unlock
2028
-1.73% 99.07%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.66 -1.33
8.29% 19.88%
P/E negative
EV/Sales 107,629.33

3 Analysts have issued a Altimmune, Inc. forecast for earnings per share. The average Altimmune, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.33
Unlock
. This is
14.19% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.28 17.42%
Unlock
, the lowest is
$-1.41 9.03%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.66 8.29%
2024
$-1.33 19.88%
Unlock
2025
$-1.37 3.01%
Unlock
2026
$-1.45 5.84%
Unlock
2027
$-1.45 0.00%
Unlock
2028
$-0.15 89.66%
Unlock

P/E ratio

Current -4.89 200.00%
2024
-5.74 17.38%
Unlock
2025
-5.54 3.48%
Unlock
2026
-5.23 5.60%
Unlock
2027
-5.25 0.38%
Unlock
2028
-50.73 866.29%
Unlock

Based on analysts' sales estimates for 2024, the Altimmune, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

107,629.33
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
144,336.00
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8,072.20 39,689.01%
2024
107,629.33 1,233.33%
Unlock
2025
16.14 99.99%
Unlock
2026
97,963.59 606,756.26%
Unlock
2027
7.31 99.99%
Unlock
2028
0.65 91.04%
Unlock

P/S ratio

Current 10,825.20 2,156.59%
2024
144,336.00 1,233.33%
Unlock
2025
21.65 99.99%
Unlock
2026
131,373.79 606,757.78%
Unlock
2027
9.80 99.99%
Unlock
2028
0.88 91.04%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today